|
| 36725433 | Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSVοG-ZEBOV-GP). | Vaccine | 2023 |
| 37289541 | Understanding the treatment benefit of hyperimmune anti-influenza intravenous immunoglobulin (Flu-IVIG) for severe human influenza. | JCI Insight | 2023 |
| 37383244 | Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive Coronavirus Disease 2019 Treatment Trial (ACTT) as a Test Case. | Open Forum Infect Dis | 2023 |
| 37474251 | A Single Case Observation: Is the Ebola Virus Soluble Glycoprotein an Indicator of Viral Recrudescence? | J Infect Dis | 2023 |
| 36801946 | Vaccination Ameliorates Cellular Inflammatory Responses in SARS-CoV-2 Breakthrough Infections. | J Infect Dis | 2023 |
| 34467402 | Fostamatinib for the Treatment of Hospitalized Adults With Coronavirus Disease 2019: A Randomized Trial. | Clin Infect Dis | 2022 |
| 36442063 | Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial. | Ann Intern Med | 2022 |
| 36415460 | Antiviral innate immunity is diminished in the upper respiratory tract of severe COVID-19 patients. | medRxiv | 2022 |
| 36394404 | Maintaining Momentum in Clinical Trials for Respiratory Viruses. | Crit Care Med | 2022 |
| 35202354 | Use of Ebola Vaccine: Expansion of Recommendations of the Advisory Committee on Immunization Practices To Include Two Additional Populations - United States, 2021. | MMWR Morb Mortal Wkly Rep | 2022 |
| 34379740 | Remdesivir for the Prevention of Invasive Mechanical Ventilation or Death in Coronavirus Disease 2019 (COVID-19): A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data. | Clin Infect Dis | 2022 |
| 33306283 | Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. | N Engl J Med | 2021 |
| 33655255 | High-Throughput, Single-Copy Sequencing Reveals SARS-CoV-2 Spike Variants Coincident with Mounting Humoral Immunity during Acute COVID-19. | bioRxiv | 2021 |
| 33831133 | High-throughput, single-copy sequencing reveals SARS-CoV-2 spike variants coincident with mounting humoral immunity during acute COVID-19. | PLoS Pathog | 2021 |
| 34268520 | Pre-vaccination and early B cell signatures predict antibody response to SARS-CoV-2 mRNA vaccine. | medRxiv | 2021 |
| 33367731 | Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic. | J Infect Dis | 2021 |
| 31541242 | Effect of Oral Oseltamivir on Virological Outcomes in Low-risk Adults With Influenza: A Randomized Clinical Trial. | Clin Infect Dis | 2020 |
| 31963118 | Modeling Challenges of Ebola Virus-Host Dynamics during Infection and Treatment. | Viruses | 2020 |
| 32053790 | Longitudinal Human Antibody Repertoire against Complete Viral Proteome from Ebola Virus Survivor Reveals Protective Sites for Vaccine Design. | Cell Host Microbe | 2020 |
| 32511445 | Detection of Nucleocapsid Antibody to SARS-CoV-2 is More Sensitive than Antibody to Spike Protein in COVID-19 Patients. | medRxiv | 2020 |
| 32427334 | Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019. | J Infect Dis | 2020 |
| 30724616 | Evaluating Promising Investigational Medical Countermeasures: Recommendations in the Absence of Guidelines. | Health Secur | 2019 |
| 31774950 | A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. | N Engl J Med | 2019 |
| 30926957 | New filovirus disease classification and nomenclature. | Nat Rev Microbiol | 2019 |
| 30779607 | The Special Pathogens Research Network: Enabling Research Readiness. | Health Secur | 2019 |
| 28929521 | Safety, tolerability, and pharmacokinetics of radavirsen (AVI-7100), an antisense oligonucleotide targeting influenza a M1/M2 translation. | Br J Clin Pharmacol | 2018 |
| 30032267 | The Past Need Not Be Prologue: Recommendations for Testing and Positioning the Most-Promising Medical Countermeasures for the Next Outbreak of Ebola Virus Infection. | J Infect Dis | 2018 |
| 29746631 | Using Clinical Research Networks to Assess Severity of an Emerging Influenza Pandemic. | Clin Infect Dis | 2018 |
| 29153266 | Ebola virus disease: an update on post-exposure prophylaxis. | Lancet Infect Dis | 2018 |
| 29329957 | Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study. | Lancet Infect Dis | 2018 |
| 25830322 | A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. | N Engl J Med | 2017 |
| 28199801 | Trial of ZMapp for Ebola Virus Infection. | N Engl J Med | 2017 |
| 28170379 | Corrigendum: Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies. | Nat Med | 2017 |
| 28193704 | <i>Pneumocystis</i> colonization in asthmatic patients not receiving oral corticosteroid therapy. | J Investig Med | 2017 |
| 28404864 | Longitudinal peripheral blood transcriptional analysis of a patient with severe Ebola virus disease. | Sci Transl Med | 2017 |
| 29308401 | Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009-2015. | Open Forum Infect Dis | 2017 |
| 28958678 | Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial. | Lancet Infect Dis | 2017 |
| 29322062 | Increased Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor Clinical Outcome in Adults Hospitalized With Influenza in the INSIGHT FLU003Plus Study. | Open Forum Infect Dis | 2017 |
| 28582513 | Evidence of Ebola Virus Replication and High Concentration in Semen of a Patient During Recovery. | Clin Infect Dis | 2017 |
| 28522352 | Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. | Lancet Respir Med | 2017 |
| 27544899 | Cardiac MRI Findings Suggest Myocarditis in Severe Ebola Virus Disease. | JACC Cardiovasc Imaging | 2017 |
| 26908739 | Design of a Randomized Controlled Trial for Ebola Virus Disease Medical Countermeasures: PREVAIL II, the Ebola MCM Study. | J Infect Dis | 2016 |
| 27732819 | A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. | N Engl J Med | 2016 |
| 27798615 | Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies. | Nat Med | 2016 |
| 27118786 | Use of Postexposure Prophylaxis After Occupational Exposure to Zaire ebolavirus. | Clin Infect Dis | 2016 |
| 27094330 | Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model. | mBio | 2016 |
| 26886522 | Clinical Management of Ebola Virus Disease in the United States and Europe. | N Engl J Med | 2016 |
| 27043004 | Severe Meningoencephalitis in a Case of Ebola Virus Disease: A Case Report. | Ann Intern Med | 2016 |
| 26830468 | A phase 1 randomized, double-blind, placebo-controlled, crossover trial of DAS181 (Fludase®) in adult subjects with well-controlled asthma. | BMC Infect Dis | 2016 |
| 25416753 | Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study. | Clin Infect Dis | 2015 |